Creative Commons source reading · Neuromodulation and neural interfaces
Cingulate dynamics track depression recovery with deep brain stimulation.
Sankaraleengam Alagapan; Ki Sueng Choi; Stephen Heisig; Patricio Riva-Posse; Andrea Crowell; Vineet Tiruvadi; Mosadoluwa Obatusin; Ashan Veerakumar; Allison C Waters; Robert E Gross; Sinead Quinn; Lydia Denison; Matthew O'Shaughnessy; Marissa Connor; Gregory Canal; Jungho Cha; Rachel Hershenberg; Tanya Nauvel; Faical Isbaine; Muhammad Furqan Afzal; Martijn Figee; Brian H Kopell; Robert Butera; Helen S Mayberg; Christopher J Rozell
Originally published in Nature · 2023-09-20
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Deep brain stimulation (DBS) of the subcallosal cingulate (SCC) can provide long-term symptom relief for treatment-resistant depression (TRD) 1 . However, achieving stable recovery is unpredictable 2 , typically requiring trial-and-error stimulation adjustments due to individual recovery trajectories and subjective symptom reporting 3 . We currently lack objective brain-based biomarkers to guide clinical decisions by distinguishing natural transient mood fluctuations from situations requiring intervention. To address this gap, we used a new device enabling electrophysiology recording to deliver SCC DBS to ten TRD participants (ClinicalTrials.gov identifier NCT01984710). At the study endpoint of 24 weeks, 90% of participants demonstrated robust clinical response, and 70% achieved remission. Using SCC local field potentials available from six participants, we deployed an explainable artificial intelligence approach to identify SCC local field potential changes indicating the patient's current clinical state. This biomarker is distinct from transient stimulation effects, sensitive to therapeutic adjustments and accurate at capturing individual recovery states.
Discussion
In this study investigating long-term multimodal changes with SCC DBS, we derived the SDC as a common objective biomarker that accurately captured clinically defined ‘sick’ and ‘stable response’ states in all patients, as well as responding to changes in DBS stimulation. In addition, the transition to reach the ‘stable response’ state identified from the SDC was correlated with structural and functional irregularities in the targeted white matter tracts and was further concordant with a data-driven analysis of complex facial expressions.
Editorial reading guide
- How were patients or cases selected, and what did the authors use as a comparator?
- Which outcomes, complications and follow-up intervals determine how far the findings apply?
